Cellectis (CLLS) Other Non-Current Assets (2014 - 2026)
Cellectis (CLLS) recorded quarterly Other Non-Current Assets of $21.3 million in Q1 2026, up 6.3% quarter-over-quarter from $20.0 million in Q4 2025, and up 58.34% on a YoY basis from $13.4 million in Q1 2025.
Cellectis (CLLS) Other Non-Current Assets (2014 - 2026) Analysis & Trends
Cellectis' Other Non-Current Assets history runs 13 years deep, the most recent figure standing at $21.3 million for Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 58.34% year-over-year to $21.3 million; the TTM figure through Mar 2026 stood at $21.3 million (up 58.34% YoY), while the FY2025 annual figure was $20.0 million, up 72.72% from the prior year.
- Other Non-Current Assets was $21.3 million for Q1 2026 at Cellectis, up from $20.0 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $21.3 million in Q1 2026 to a low of $175000.0 in Q1 2022.
- Historically, Other Non-Current Assets has averaged $13.5 million across 5 years, with a median of $13.4 million in 2025.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Assets tumbled 99.21% in 2022, then soared 11405.71% in 2023.
- A 5-year view of Other Non-Current Assets shows it stood at $8.8 million in 2022, then decreased by 10.67% to $7.9 million in 2023, then soared by 47.64% to $11.6 million in 2024, then jumped by 72.72% to $20.0 million in 2025, then advanced by 6.3% to $21.3 million in 2026.
- The last three Other Non-Current Assets figures came in at $21.3 million (Q1 2026), $20.0 million (Q4 2025), and $18.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 60,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Cellectis | 17.40 Bn | 17.21 Bn | - | 21.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.29 Mn |
| Dec 31, 2025 | 20.03 Mn |
| Sep 30, 2025 | 18.18 Mn |
| Jun 30, 2025 | 16.13 Mn |
| Mar 31, 2025 | 13.44 Mn |
| Dec 31, 2024 | 11.59 Mn |
| Sep 30, 2024 | 11.12 Mn |
| Dec 31, 2023 | 7.85 Mn |
| Mar 31, 2023 | 20.14 Mn |
| Dec 31, 2022 | 8.79 Mn |
| Mar 31, 2022 | 175,000.00 |
| Dec 31, 2021 | 6.52 Mn |
| Sep 30, 2021 | 22.05 Mn |
| Jun 30, 2021 | 22.10 Mn |
| Mar 31, 2021 | 22.11 Mn |
| Dec 31, 2020 | 7.01 Mn |
| Sep 30, 2020 | 9.78 Mn |
| Jun 30, 2020 | 7.38 Mn |
| Mar 31, 2020 | 7.48 Mn |
| Dec 31, 2019 | 5.52 Mn |